Chlorproguanil/dapsone/artesunate (abbreviated CDA) was an experimental antimalarial treatment that entered Phase III clinical trials in 2006. Development was halted because it was associated with an increased risk of haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase deficiency.[1]
| Combination of | |
|---|---|
| Chlorproguanil | Antimalarial drug |
| Dapsone | Antibiotic |
| Artesunate | Antimalarial drug |
| Legal status | |
| Legal status |
|
| Identifiers | |
| ChemSpider |
|
It consists of chlorproguanil, dapsone, and artesunate. (It can also be interpreted as Lapdap+artesunate.)
Studies compared this combination against artemether/lumefantrine (Coartem) and against chlorproguanil/dapsone (Lapdap). This drug was developed in collaboration between GlaxoSmithKline, UNICEF, the World Bank, Medicines for Malaria Venture and the WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR), the Liverpool School of Tropical Medicine, and the London School of Hygiene and Tropical Medicine.[2]
References
edit- ^ Van Malderen C, Van Geertruyden JP, Machevo S, González R, Bassat Q, Talisuna A, et al. (July 2012). "Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria". Malaria Journal. 11: 139. doi:10.1186/1475-2875-11-139. PMC 3393623. PMID 22546009.
- ^ Das P (2006). "Promising anti-malarial enters phase II studies". Lancet Infect Dis. 6 (9): 551. doi:10.1016/S1473-3099(06)70571-0.
External links
edit | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |